StockData
Attovia Therapeutics, Inc. logo

Attovia Therapeutics, Inc. (ATTO) stock

ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$14.86+0.13 (+0.92%)

Close on Nov 17, 2026Market cap $678.38MP/E –Yield –

Attovia Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$24.82M–
Q2 FY2026Jun 30, 2026-$21.60M–
Q3 FY2025Sep 30, 2025-$15.40M–
Q2 FY2025Jun 30, 2025-$16.42M–

More Attovia Therapeutics figures

See a number that looks wrong?